Literature DB >> 380616

History and development of mixed opioid agonists, partial agonists and antagonists.

W R Martin.   

Abstract

1 A brief history of the development of narcotic antagonists is outlined. 2 The clinical and pharmacological observations leading to the discovery of dualism of opiate receptors are reviewed. 3 An extension of this theory to a three-receptor model (mu, kappa and sigma) is required to rationalize the pharmacology of the antagonists analgesics cyclazocine, pentazocine and nalorphine. 4 The methodologies available for the study of compounds with dual agonist-antagonist activity are discussed in the light of the above receptor multiplicity, and data appertaining to the kappa-partial agonist, nalorphine and the mu-partial agonist buprenorphine are outlined.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 380616      PMCID: PMC1429308          DOI: 10.1111/j.1365-2125.1979.tb04700.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES.

Authors:  L S HARRIS; A K PIERSON
Journal:  J Pharmacol Exp Ther       Date:  1964-02       Impact factor: 4.030

2.  Narcotic antagonists as analgesics.

Authors:  S ARCHER; N F ALBERTSON; L S HARRIS; A K PIERSON; J G BIRD; A S KEATS; J TELFORD; C N PAPADOPOULOS
Journal:  Science       Date:  1962-08-17       Impact factor: 47.728

3.  N-Allylnormorphine: effects of single doses and precipitation of acute abstinence syndromes during addiction to morphine; methadone or heroin in man (post addicts).

Authors:  A WIKLER; H F FRASER; H ISBELL
Journal:  J Pharmacol Exp Ther       Date:  1953-09       Impact factor: 4.030

4.  Addiction to analgesics and barbiturates.

Authors:  H ISBELL; H F FRASER
Journal:  J Pharmacol Exp Ther       Date:  1950-08       Impact factor: 4.030

5.  Pharmacological redundancy as an adaptive mechanism in the central nervous system.

Authors:  W R Martin
Journal:  Fed Proc       Date:  1970 Jan-Feb

6.  Effects of short- and long-term administration of pentazocine in man.

Authors:  D R Jasinski; W R Martin; R D Hoeldtke
Journal:  Clin Pharmacol Ther       Date:  1970 May-Jun       Impact factor: 6.875

7.  Demonstration of tolerance to and physical dependence of N-allylnormorphine (nalorphine).

Authors:  W R Martin; C W Gorodetzky
Journal:  J Pharmacol Exp Ther       Date:  1965-12       Impact factor: 4.030

8.  Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine, WIN-20,740, ARC II-c-3).

Authors:  W R Martin; H F Fraser; C W Gorodetzky; D E Rosenberg
Journal:  J Pharmacol Exp Ther       Date:  1965-12       Impact factor: 4.030

9.  Sigma effects of nalorphine in the chronic spinal dog.

Authors:  P E Gilbert; W R Martin
Journal:  Drug Alcohol Depend       Date:  1976-10       Impact factor: 4.492

10.  The analgesic effectiveness of codeine and meperidine (demerol).

Authors:  L LASAGNA; H K BEECHER
Journal:  J Pharmacol Exp Ther       Date:  1954-11       Impact factor: 4.030

View more
  19 in total

1.  Animal and molecular pharmacology of mixed agonist-antagonist analgesic drugs.

Authors:  M J Rance
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Cross-tolerance and enhanced sensitivity to the response rate-decreasing effects of opioids with varying degrees of efficacy at the mu receptor.

Authors:  M J Picker; J Yarbrough
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  75 years of opioid research: the exciting but vain quest for the Holy Grail.

Authors:  Alistair D Corbett; Graeme Henderson; Alexander T McKnight; Stewart J Paterson
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

5.  [Long-term application of opioids in chronic noncancer pain (LONTS 2): Urgently required new guidelines].

Authors:  R-D Treede; M Zenz
Journal:  Schmerz       Date:  2015-02       Impact factor: 1.107

6.  Tolerance to the mydriatic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine in mice.

Authors:  M Kaadan; A Stav; R Rabinowitz; S Shavit; A D Korczyn
Journal:  J Anesth       Date:  1994-09       Impact factor: 2.078

7.  Clinical efficacy of sustained-release buprenorphine with meloxicam for postoperative analgesia in beagle dogs undergoing ovariohysterectomy.

Authors:  Elizabeth A Nunamaker; DeAnne F Stolarik; Junli Ma; Amanda S Wilsey; Gary J Jenkins; Chris L Medina
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

8.  Mixed agonist-antagonist opiates and physical dependence.

Authors:  J J Jacob; G M Michaud; E C Tremblay
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

9.  Action of opioid agonist-antagonist drugs on the pupil and nociceptive responses in mice.

Authors:  A Stav; R Rabinowitz; A D Korczyn
Journal:  J Anesth       Date:  1992-10       Impact factor: 2.078

Review 10.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective.

Authors:  Sonia Podvin; Tony Yaksh; Vivian Hook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.